Evidence map›Paper›PMID 39041943›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Validating Combination Throat-Nasal Swab Specimens for COVID-19 Tests Would Improve Early Detection, Especially for the Most Vulnerable.

Alexander Viloria Winnett, Timothy Stenzel, Rustem F Ismagilov

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexander Viloria WinnettDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, USA.ORCID 0000-0002-7338-5605
Timothy StenzelOffice of In Vitro Diagnostics, US Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0003-4299-910X
Rustem F IsmagilovDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California, USA.ORCID 0000-0002-3680-4399

Funding

Longitudinal mucosal immune response to SARS-CoV-2 starting prior to infectionF30AI167524 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI VILORIA WINNETT, ALEXANDER · 2022 to 2024
$127k
California Institute of TechnologyNIAID NIH HHS F30 AI167524
6 · The paper itself

Abstract

Early detection of severe acute respiratory syndrome coronavirus 2 infection by diagnostic tests can prompt actions to reduce transmission and improve treatment efficacy, especially for vulnerable groups such as immunocompromised individuals. Recent evidence suggests that sampling the throat in addition to the nose improves clinical sensitivity during early infection for both antigen and molecular coronavirus disease 2019 tests. We urge test manufacturers to validate tests for use with throat swab, in combination with nasal swabs.

Indexed as

COVID-19NosePharynxSARS-CoV-2Specimen HandlingCOVID-19 TestingEarly DiagnosisHumansSensitivity and SpecificityCOVID-19early detectionrapid diagnosticsspecimen typesvalidation testing

Identifiers

PMID39041943
PMCPMC11478585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.